New Delhi, Feb. 21 -- India has developed a novel antibiotic to fight antimicrobial resistance (AMR), as well as a new drug to tackle burden of kala-azar, also known as visceral leishmaniasis (VL) in the country, deliberated eminent scientists on Friday. The experts were speaking on the second day of the 9th International Symposium on Current Trends in Drug Discovery Research at CSIR-Central Drug Research Institute in Lucknow.

The event saw experts from different areas share their recent findings on drug resistance, Car T-cell therapy for cancer care, and parasitic and viral diseases. Prof. Shyam Sundar from the Banaras Hindu University, Varanasi, shared the journey of the epidemic of visceral leishmaniasis (VL), starting from its origin...